CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 567 enrolled
Drug / intervention
Bimekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03370133
NCT03370133Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

UCB Biopharma SRL·interventional·Posted Dec 12, 2017·Updated Apr 15, 2026

In Brief

A Phase 3 clinical trial evaluating Bimekizumab, Ustekinumab, and 1 other intervention for Chronic Plaque Psoriasis and 2 related conditions. Completed, enrolled 567 participants across 105 sites in 11 countries.

Detailed Summary

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
CountriesAustralia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russia, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 12, 2017
Enrollment StartDec 6, 2017
Primary CompletionJan 8, 2019
Study CompletionDec 13, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.6 years ago

Interventions

Bimekizumabdrug

Bimekizumab will be provided at pre-specified time intervals.

Ustekinumabdrug

Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.

Placeboother

Subjects will receive Placebo at pre-specified time points.